SEC Tracker
Get the app
VTVT · XBRL financial data

vTv Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (VTVT's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers00*1,0000017*0000*36,8390
Research and development2,8242,138*2,6493,4393,2242,234*2,8304,1037,0203,908*8,9788,770
General and administrative2,5442,569*3,9783,7163,2822,675*3,6733,6183,6793,977*4,5985,160
Total operating expenses5,3684,707*6,6277,1556,5064,909*6,5037,72110,6997,885*13,57613,930
Operating income (loss)(5,368)(4,707)*(5,627)(7,155)(6,506)(4,892)*(6,503)(7,721)(10,699)(7,885)*23,263(13,930)
Interest income13188*79553504429*331275399865*838812
Interest expense47*———year only——————
Other income (expense)—year only——————————
Income tax expense (benefit)00*100000*0000*00
Net income (loss)(6,654)(3,478)*(4,865)(5,180)(4,783)(3,634)*(5,092)(6,046)(8,698)(7,138)*24,134(13,054)

Balance sheet

CSV

Fiscal quarters (VTVT's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents8,2389,44652,25545,52641,57136,74631,05925,92298,50488,93298,08686,643
Accounts receivable010298130624262——————
Prepaid and other current assets1,8721,0445713031,0601,220———961——
Total current assets10,12510,65753,87246,20042,95838,11331,91626,37499,45689,89398,80887,589
Property and equipment, net14011795725028191614———
Right-of-use asset272244216186156125925824———
Total assets14,92411,01854,18346,45843,16438,26632,02726,44899,49489,89998,81387,593
Accounts payable—4,075———939———1,132——
Total current liabilities10,27510,6198,9216,9856,4245,1964,3165,29510,1636,6416,8817,017
Lease liability, non-current21316912579320——————
Total liabilities29,43529,56728,19626,02125,25123,96523,13024,04328,95125,4628,8548,961
Accumulated deficit(281,192)(281,042)(286,121)(291,301)(296,084)(299,718)(304,810)(310,856)(319,554)(326,692)(302,558)(315,612)
Total stockholders' equity(25,233)(24,680)20,79616,47515,00812,1997,9202,76270,54364,43789,95978,632
Total liabilities and equity14,92411,01854,18346,45843,16438,26632,02726,44899,49489,89998,81387,593

Cash flows

CSV

Fiscal quarters (VTVT's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(6,654)(3,478)*(4,865)(5,180)(4,783)(3,634)*(5,092)(6,046)(8,698)(7,138)*24,134(13,054)
Stock-based compensation433*403*220859*853*825*813930*1,007*1,025*1,3881,727*
Net cash from operating activities(4,834)*(2,914)*(7,335)(6,729)*(6,418)*(4,825)*(5,687)(5,095)*(5,222)*(9,251)*9,154(11,443)*
Purchases of property and equipment0*0*———year only——————
Net cash from investing activities0*4,404*———year only———year only——
Proceeds from issuing common stock0*0*———0*———0*——
Net cash from financing activities473*(282)*50,1440*2,463*0*0(42)*77,804*(321)*——
Net change in cash(4,361)*1,208*42,809(6,729)*(3,955)*(4,825)*(5,687)(5,137)*72,582*(9,572)*9,154(11,443)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
vTv Therapeutics86,6430(11,443)*not reported7.6 quarters 10-QJun 30, 2026
Ovid Therapeutics11,327733(17,594)*195.3M6.7 quarters 10-QJun 30, 2026
Marimed8,43741,9252,219*403.0M— 10-QJun 30, 2026
Aptose Biosciences1,020not reported(5,841)2.6M0.2 quarters 10-QMar 31, 2026
Dare Bioscience12,618188(6,775)*15.3M1.9 quarters 10-QJun 30, 2026
Lunai Bioworks1,71431*(1,841)*5.0M0.9 quarters 10-KJun 30, 2026
Imunon6,864not reported(3,025)*5.6M2.3 quarters 10-QJun 30, 2026
Lisata Therapeutics10,4430(2,649)*9.0M3.9 quarters 10-QJun 30, 2026
Nanoviricides2,794not reported(2,122)*25.5M1.3 quarters 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.